Openfund

CORDIS · RELEVIUM

Improving quality of life of advanced pancreatic cancer patients through an AI-guided multimodal intervention, combining pain and cachexia management, nutrition, and physical activity

Код
RELEVIUM
Програма
HORIZON
Процедура
HORIZON-HLTH-2021-DISEASE-04-01
Статус
SIGNED
Период
01.09.2022 – 30.11.2026
Обща стойност (целият консорциум)5 997 312 €
Принос на ЕС (целият консорциум)5 997 312 €
Принос на ЕС за българските участници500 625 €

Официални данни · CORDIS · синхронизирано 17.10.2026 10:16 · официален запис

Участници

ОрганизацииРоляДържаваБезвъзмездна помощ
UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZкоординаторDE804 091 €
ROSENBAUM CONSULTINGучастникBG500 625 €
CHAROKOPEIO PANEPISTIMIOучастникEL500 000 €
JOHANNES GUTENBERG-UNIVERSITAT MAINZучастникDE500 000 €
EXUS SOFTWARE MONOPROSOPI ETAIRIA PERIORISMENIS EVTHINISучастникEL475 000 €
MCS DATALABSучастникDE417 812 €
ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXISучастникEL412 500 €
AINIGMA TECHNOLOGIESучастникBE350 000 €
FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EVучастникDE308 750 €
THE HEALTH CORPORATION - RAMBAMучастникIL280 630 €
PULSIFY MEDICAL BVучастникBE230 891 €
FUTURO PERFECTO INNOVACION SLучастникES223 875 €
SIHTASUTUS POHJA-EESTI REGIONAALHAIGLAучастникEE215 630 €
INSTITUT CURIEучастникFR200 000 €
DIADIKASIA BUSINESS CONSULTING SYMVOULOI EPICHEIRISEON AEучастникEL179 375 €
ASSOCIATION HOSPITALIERE DE BRUXELLES-CENTRE HOSPITALIER UNIVERSITAIRE JULES BORDETучастникBE150 000 €
STICHTING EUROPEAN NUTRITION FOR HEALTH ALLIANCEучастникNL146 258 €
CSI CENTER FOR SOCIAL INNOVATION LTDучастникCY101 875 €
EUROPEAN CANCER PATIENT COALITIONучастникBE0 €

Описание

Pancreatic cancer has the lowest survival rate amongst other cancers and is responsible for 95,000 deaths every year in the EU. Its treatment is usually palliative, aiming at slowing tumour progression and at symptom management.The main hypothesis of RELEVIUM is that quality of life (QoL) of advanced pancreatic cancer patients can be significantly improved by reducing pain and cachexia through highly personalised nutrition, physical activity, and pain management strategies, in addition to chemotherapy treatment. To achieve this, RELEVIUM will empower patients with digital tools that facilitate patient-doctor communication and enable them to self-manage their disease. RELEVIUM will use (i) a multi-sensor smartwatch and an innovative remote ultrasound patch, (ii) AI algorithms for continuous remote monitoring of pain and sarcopenia, as well as for decision support, and (iii) patient and caregiver applications. Combined, these tools will provide a stream of evidence on symptom progression and will enable physicians to apply personalised care plans.RELEVIUM brings together an interdisciplinary team of experts and will also involve patients and their caregivers in an iterative co-creation process. The project will initially conduct a feasibility and data collection study (RELEVIUM-FDC, n=130). The study aims at optimizing patient adherence and compliance, and at collecting data for the development of the intervention. A five-centre randomized clinical trial (RELEVIUM-RCT) will then evaluate the efficacy of the proposed personalised care plans for advanced pancreatic cancer patients (n=132) in terms of their QoL. Several secondary outcomes will be investigated, such as the cost-effectiveness of the intervention, its potential in increasing health equity and in relieving the stress burden on the patient families.The study outcomes will result in recommendations for integrating remote monitoring and improving QoL outcomes in palliative care for advanced pancreatic cancer

Официални данни · CORDIS · синхронизирано 17.10.2026 10:16 · официален запис · Лиценз: © European Union, CC BY 4.0 (Commission reuse policy).